Zhang M, Wan P, Ng K, Singh K, Cheng TH, Velickovic I, Dalloul M, Wlody D.
Abstract
Importance: Preeclampsia is a devastating disease of pregnancy associated with increased risk of fetal and maternal complications. African American pregnant women have a high prevalence of preeclampsia, but there is a need of systemic analyses of this high-risk group regarding complications, etiology, and biomarkers.
Objective: The aim of this study was to provide a synopsis of current research of preeclampsia specifically related to African American women.
Evidence acquisition: A comprehensive search was performed in the bibliographic database PubMed with keywords "preeclampsia" and "African American."
Results: African American women with preeclampsia were at an increased risk of preterm birth, which resulted in low-birth-weight infants. Intrauterine fetal death among African American preeclamptic patients occurs at twice the rate as in other races. On the maternal side, African American mothers with preeclampsia have more severe hypertension, antepartum hemorrhage, and increased mortality. Those who survive preeclampsia have a high risk of postpartum cardiometabolic disease. Preexisting conditions (eg, systemic lupus erythematosus) and genetic mutations (eg, sickle cell disease in the mother, FVL or APOL1 mutations in the fetus) may contribute to the higher prevalence and worse outcomes in African American women. Many blood factors, for example, the ratio of proteins sFlt/PlGF, hormones, and inflammatory factors, have been studied as potential biomarkers for preeclampsia, but their specificity needs further investigation.
Conclusions: Further studies of preeclampsia among African American women addressing underlying risk factors and etiologies, coupled with identification of preeclampsia-specific biomarkers allowing early detection and intervention, will significantly improve the clinical management of this devastating disease.
Similar articles
Relationships among psychosocial factors, biomarkers, preeclampsia, and preterm birth in African American women: a pilot. Giurgescu C, Sanguanklin N, Engeland CG, White-Traut RC, Park C, Mathews HL, Janusek LW.Appl Nurs Res. 2015 Feb;28(1):e1-6. doi: 10.1016/j.apnr.2014.09.002. Epub 2014 Sep 16.PMID: 25282477
Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement.
US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phillips WR, Phipps MG, Silverstein M, Simon MA, Tseng CW.JAMA. 2017 Apr 25;317(16):1661-1667. doi: 10.1001/jama.2017.3439.PMID: 28444286
Fetal-Not Maternal-APOL1 Genotype Associated with Risk for Preeclampsia in Those with African Ancestry. Reidy KJ, Hjorten RC, Simpson CL, Rosenberg AZ, Rosenblum SD, Kovesdy CP, Tylavsky FA, Myrie J, Ruiz BL, Haque S, Mozhui K, Nelson GW, David VA, Yang X, Suzuki M, Jacob J, Reznik SE, Kaskel FJ, Kopp JB, Winkler CA, Davis RL.Am J Hum Genet. 2018 Sep 6;103(3):367-376. doi: 10.1016/j.ajhg.2018.08.002. Epub 2018 Aug 30.PMID: 30173819Free PMC article.
Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Henderson JT, Whitlock EP, O'Conner E, Senger CA, Thompson JH, Rowland MG.Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Apr. Report No.: 14-05207-EF-1.PMID: 24783270Free Books & Documents.Review.
Diagnostic Potential of MicroRNAs as Biomarkers in the Detection of Preeclampsia. Hornakova A, Kolkova Z, Holubekova V, Loderer D, Lasabova Z, Biringer K, Halasova E.Genet Test Mol Biomarkers. 2020 Jun;24(6):321-327. doi: 10.1089/gtmb.2019.0264.PMID: 32511062Review.